Tela Bio Inc Net Assets
Tela Bio Inc net assets. Based on the latest financial reports, Tela Bio Inc (TELA) has net assets worth $-15.87 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($59.74 Million) and total liabilities ($75.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Tela Bio Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-15.87 Million |
| % of Total Assets | -26.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | -68.59% |
| 10-Year Change | N/A |
| Growth Volatility | 53.65 |
Net Assets of Tela Bio Inc (2017–2025)
Net assets of Tela Bio Inc from 2017 to 2025. This chart illustrates how Tela Bio Inc's net assets have evolved over time, based on quarterly financial data. See TELA net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Tela Bio Inc (2017–2025)
The table below shows the annual net assets of Tela Bio Inc from 2017 to 2025. For live market cap and overall valuation, see TELA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.31 Million | -77.82% |
| 2024-12-31 | $28.46 Million | +50.72% |
| 2023-12-31 | $18.88 Million | +31.99% |
| 2022-12-31 | $14.30 Million | -28.82% |
| 2021-12-31 | $20.10 Million | -59.01% |
| 2020-12-31 | $49.03 Million | +58.34% |
| 2019-12-31 | $30.96 Million | +122.46% |
| 2018-12-31 | $-137.86 Million | -27.45% |
| 2017-12-31 | $-108.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tela Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28939000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Tela Bio Inc Net Assets Breakdown (December 2025)
Tela Bio Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $44.00K | 0.70% |
| Other Comprehensive Income | $91.00K | 1.44% |
| Other Components | $403.74 Million | 6395.36% |
| Total Equity | $6.31 Million | 100.00% |
Tela Bio Inc Competitors by Market Cap
The table below lists competitors of Tela Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hammer Metals Ltd
AU:HMX
|
$36.01 Million |
|
INFOMARK Co. Ltd
KQ:175140
|
$36.01 Million |
|
NBI Bearings Europe S.A.
MC:NBI
|
$36.01 Million |
|
Woory Industrial Co. Ltd
KQ:215360
|
$36.02 Million |
|
S&S Power Switchgears Limited
NSE:S&SPOWER
|
$36.00 Million |
|
IBKS No2 SPAC
KQ:204840
|
$36.00 Million |
|
Beaconsmind AG
PA:MLBMD
|
$35.99 Million |
|
TAEYANG Corporation
KQ:053620
|
$35.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tela Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,458,000 to 6,313,000, a change of -22,145,000 (-77.8%).
- Net loss of 38,831,000 reduced equity.
- Share repurchases of 105,000 reduced equity.
- New share issuances of 11,823,000 increased equity.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 4,967,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.83 Million | -615.1% |
| Share Repurchases | $105.00K | -1.66% |
| Share Issuances | $11.82 Million | +187.28% |
| Other Comprehensive Income | $1.00K | +0.02% |
| Other Changes | $4.97 Million | +78.68% |
| Total Change | $- | -77.82% |
Book Value vs Market Value Analysis
This analysis compares Tela Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-16.67 | $0.80 | x |
| 2018-12-31 | $-21.25 | $0.80 | x |
| 2019-12-31 | $2.71 | $0.80 | x |
| 2020-12-31 | $3.79 | $0.80 | x |
| 2021-12-31 | $1.39 | $0.80 | x |
| 2022-12-31 | $0.88 | $0.80 | x |
| 2023-12-31 | $0.83 | $0.80 | x |
| 2024-12-31 | $1.00 | $0.80 | x |
| 2025-12-31 | $0.13 | $0.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tela Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -615.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48.37%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 12.90x
- Recent ROE (-615.10%) is below the historical average (-177.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -502.57% | 0.27x | 0.00x | $-10.52 Million |
| 2018 | 0.00% | -254.92% | 0.30x | 0.00x | $-7.31 Million |
| 2019 | -72.43% | -145.18% | 0.23x | 2.19x | $-25.52 Million |
| 2020 | -58.73% | -158.10% | 0.21x | 1.76x | $-33.70 Million |
| 2021 | -165.57% | -112.94% | 0.47x | 3.11x | $-35.29 Million |
| 2022 | -309.65% | -106.95% | 0.61x | 4.74x | $-45.73 Million |
| 2023 | -247.15% | -79.83% | 0.75x | 4.13x | $-48.55 Million |
| 2024 | -132.97% | -54.60% | 0.79x | 3.07x | $-40.69 Million |
| 2025 | -615.10% | -48.37% | 0.99x | 12.90x | $-39.46 Million |
Industry Comparison
This section compares Tela Bio Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tela Bio Inc (TELA) | $-15.87 Million | 0.00% | N/A | $36.01 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more